Drug Trial News

RSS

New antibody can reduce swelling attacks in patients with hereditary angioedema

Patients with hereditary angioedema experience recurrent and sometimes life-threatening swelling attacks. Researchers from Charité - Universitätsmedizin Berlin have tested an antibody capable of reducing the frequency of these swelling attacks by more than 90 percent.

28 Nov 2018

Botulinum toxin injections show promise to suppress postoperative atrial fibrillation

Postoperative atrial fibrillation is a common complication, affecting one quarter to one half of all patients following cardiac surgery.

28 Nov 2018

New drug shows promise for treating people with peanut allergy

Controlled ingestion of peanut protein could help build tolerance in peanut allergy sufferers. Authors of a new study published in the New England Journal of Medicine say an oral immunotherapy drug they tested could be the first FDA-approved medication of its kind for people with peanut allergy.

19 Nov 2018

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

An antibody that binds simultaneously to two distinct regions of the HER2 receptor to block the growth of cancer cells has shown promising signs of anti-tumor activity in a number of cancers including those of the gullet (esophagus), stomach and bowel.

14 Nov 2018

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

When it comes to reducing inflammation to decrease the risk of heart disease and stroke, results from the much-anticipated Cardiovascular Inflammation Reduction Trial indicate that targeting the right inflammatory pathways in at-risk patients is crucial.

12 Nov 2018

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

A phase 2 clinical trial led by Stephanie N. Taylor, MD, Professor of Medicine and Microbiology in the Section of Infectious Diseases at LSU Health New Orleans School of Medicine, has found that a new antibiotic effectively treats uncomplicated urogenital and rectal gonorrhea infections in a single oral dose.

9 Nov 2018

Oral antibiotic shows promise to cure uncomplicated gonorrhea

An investigational oral antibiotic called zoliflodacin was well-tolerated and successfully cured most cases of uncomplicated gonorrhea when tested in a Phase 2 multicenter clinical trial, according to findings published today in the New England Journal of Medicine.

8 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Ark Biosciences, a biotech company developing proprietary therapeutics for viral infection and respiratory diseases, announced today the significant progress in its phase 2 proof-of-concept study of ziresovir in the treatment of hospitalized RSV infected infants.

1 Nov 2018

Phase 2 STEMTRA trial using SB623 cells for treating traumatic brain injury meets primary endpoint

The SanBio Group announces today that the Phase 2 STEMTRA trial using SB623 cells for the treatment of patients with traumatic brain injury, met its primary endpoint.

1 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge.

30 Oct 2018

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data highlighting how the accuracy of the DecisionDx-Melanoma gene expression profile (GEP) test in patients with Stage II and IIIA melanoma can improve adjuvant clinical trial design at the 2018 Society for Melanoma Research International Congress held in Manchester, England from October 24-27.

30 Oct 2018

AEGEA Medical begins PACE II clinical study in women who underwent endometrial ablation

AEGEA Medical, Inc. has announced the commencement of the Post-Ablation Cavity Access (PACE II) clinical study in women who previously underwent endometrial ablation as part of AEGEA's pivotal trial of the company's patented Adaptive Vapor Ablation technology.

30 Oct 2018

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Two clinical trials of an investigational drug that targets the opioid system support its safety and effectiveness in reducing symptoms of major depression, when added to standard antidepressant treatment.

29 Oct 2018

Hormone injections reduce risk for early menopause from breast cancer chemotherapy

Final results of SWOG Cancer Research Network's groundbreaking international Prevention of Early Menopause Study clinical trial are in, and they show continued evidence that women who get injections of the hormone drug goserelin along with standard breast cancer chemotherapy are more likely to become pregnant - without developing negative side effects or shortening their lives.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

High-impact clinical trial results could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented at ASN Kidney Week 2018 October 23-October 28 at the San Diego Convention Center.

26 Oct 2018

The Lancet Infectious Diseases journal publishes clinical trial results for Shionogi’s cefiderocol

Shionogi & Co., Ltd. announced today that The Lancet Infectious Diseases journal has published clinical results from the pivotal randomized controlled trial evaluating cefiderocol for the treatment of complicated urinary tract infection in patients at risk of multidrug-resistant Gram-negative infections.

26 Oct 2018

Drug Trial News

New antibody can reduce swelling attacks in patients with hereditary angioedema

Botulinum toxin injections show promise to suppress postoperative atrial fibrillation

New drug shows promise for treating people with peanut allergy

New anti-HER2 drug shows promising anti-tumor activity in gullet, stomach and bowel cancers

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

New single-dose antibiotic effectively treats uncomplicated gonorrhea infections

Oral antibiotic shows promise to cure uncomplicated gonorrhea

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Phase 2 STEMTRA trial using SB623 cells for treating traumatic brain injury meets primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

AEGEA Medical begins PACE II clinical study in women who underwent endometrial ablation

Investigational drug targeting the opioid system may help reduce symptoms of major depression

Hormone injections reduce risk for early menopause from breast cancer chemotherapy

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

High-impact clinical trial results could affect kidney-related medical care

The Lancet Infectious Diseases journal publishes clinical trial results for Shionogi’s cefiderocol

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News